We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Vistagen's pipeline includes six product candidates, including five ... Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Vistagen's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. Its portfolio includes PH94B, a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia. PH10, an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression. Show more
Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host...
Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing PALISADE-3 and PALISADE-4 Phase 3 trials initiated and...
Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new...
Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on...
Vistagen CEO Shawn Singh; The Goldie Hawn Foundation Founder Goldie Hawn; and MindUP students to ring the Nasdaq Closing Bell on October 10, 2024 Vistagen and The Goldie Hawn Foundation join...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.145 | -5.44090056285 | 2.665 | 2.9 | 2.52 | 163512 | 2.67811516 | CS |
4 | -0.61 | -19.4888178914 | 3.13 | 3.235 | 2.48 | 235943 | 2.73455308 | CS |
12 | -0.67 | -21.0031347962 | 3.19 | 3.34 | 2.48 | 203189 | 2.93198883 | CS |
26 | -1.36 | -35.0515463918 | 3.88 | 4.21 | 2.48 | 151277 | 3.14681504 | CS |
52 | -1.79 | -41.5313225058 | 4.31 | 5.86 | 2.48 | 228961 | 4.31549504 | CS |
156 | -47.58 | -94.9700598802 | 50.1 | 63.3 | 1.62 | 3027119 | 8.3801655 | CS |
260 | -10.806 | -81.0895992796 | 13.326 | 106.5 | 1.62 | 2516724 | 21.66732208 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions